Abstract
To discover non-nucleoside inhibitors of HIV-1 reverse transcriptase (NNRTIs) that are effective against both wild-type (WT) virus and variants that encode the clinically troublesome Tyr181Cys (Y181C) RT mutation, virtual screening by docking was carried out using three RT structures and more than 2 million commercially available compounds. Two of the structures are for WT-virus with different conformations of Tyr181, while the third structure incorporates the Y181C modification. Eventually nine compounds were purchased and assayed. Three of the compounds show low-micromolar antiviral activity toward either or both the wild-type and Y181C HIV-1 strains. The study illustrates a viable protocol to seek anti-HIV agents with enhanced resistance profiles. © 2009 American Chemical Society.
Cite
CITATION STYLE
Nichols, S. E., Domaoal, R. A., Thakur, V. V., Tirado-Rives, J., Anderson, K. S., & Jorgensen, W. L. (2009). Discovery of wild-type and Y181C mutant non-nucleoside HIV-1 reverse transcriptase inhibitors using virtual screening with multiple protein structures. Journal of Chemical Information and Modeling, 49(5), 1272–1279. https://doi.org/10.1021/ci900068k
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.